Key result
In patients with acute myocardial infarction treated with PCI, previously known diabetes, new-onset diabetes, and impaired glucose tolerance increased long-term mortality compared to normal glucose tolerance.
Why the study?
Do glucose abnormalities (IGT, new onset DM, known DM) increase long-term mortality in AMI patients treated with PCI compared to normal glucose tolerance?
Observational (n=2,527)
No
Do glucose abnormalities (IGT, new onset DM, known DM) increase long-term mortality in AMI patients treated with PCI compared to normal glucose tolerance?
Impaired glucose tolerance and new-onset diabetes confer a similar long-term mortality risk as known diabetes in patients with AMI treated with PCI.
Answers are grounded in this paper and cite their sources.
Glucose abnormalities may warrant closer post-PCI AMI risk stratification; leaves open whether targeted intervention improves outcomes in this cohort.
BACKGROUND: Diabetes (DM) deteriorates the prognosis in patients with coronary heart disease. However, the prognostic value of different glucose abnormalities (GA) other than DM in subjects with acute myocardial infarction (AMI) treated invasively remains unclear. AIMS: To assess the incidence and impact of GA on clinical outcomes in AMI patients treated with percutaneous coronary intervention (PCI). METHODS: A single-center, prospective registry encompassed 2733 consecutive AMI subjects treated with PCI. In all in-hospital survivors (n = 2527, 92.5%) without the history of DM diagnosed before or during index hospitalization standard oral glucose tolerance test (OGTT) was performed during stable condition before hospital discharge and interpreted according to WHO criteria. The mean follow-up period was 37.5 months. RESULTS: The incidence of GA was as follows: impaired fasting glycaemia - IFG (n = 376, 15%); impaired glucose tolerance - IGT (n = 560, 22%); DM (n = 425, 17%); new onset DM (n = 384, 15%); and normal glucose tolerance - NGT (n = 782, 31%). During the long-term follow-up, death rate events for previously known DM, new onset DM and IGT were significantly more frequent than those for IFG and NGT (12.3; 9.6 and 9.4 vs. 5.6 and 6.4%, respectively, P < 0.05). The strongest and common independent predictors of death in GA patients were glomerular filtration rate < 60 ml/min/1,73 m^2 (HR 2.0 and 2.8) and left ventricle ejection fraction < 35% (HR 2.5 and 1.8, all P < 0.05) respectively. CONCLUSIONS: Glucose abnormalities are very common in AMI patients. DM, new onset DM and IGT increase remote mortality. Impaired glucose tolerance bears similar long-term prognosis as diabetes.
No takes yet. Share an insight, caveat, or question.
Mazurek et al. (2012) conducted an observational in Acute myocardial infarction (n=2,527). Glucose abnormalities (diabetes, new-onset diabetes, impaired glucose tolerance) vs. Normal glucose tolerance was evaluated on Death from any cause (p=<0.05). In patients with acute myocardial infarction treated with PCI, previously known diabetes, new-onset diabetes, and impaired glucose tolerance increased long-term mortality compared to normal glucose tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: